Skip to main content

Our Impact

Our Impact

See how our high-quality academic work is benefitting people across the globe.

Changing the world for the better

  • A new technique to prevent transmission of mitochondrial disease 
  • Approval of eculizumab and establishment of a national service to treat patients with Atypical Haemolytic Uraemic Syndrome
  • Ataluren: the first approved oral treatment for Duchenne muscular dystrophy
  • Human-derived limbal cell transplant to treat chemical burns of the eye
  • Erdafitinib, the first-in-class treatment of bladder cancer
  • Fibrofind, a stable human alternative for testing anti-fibrotic drugs
  • Aspirin to decrease the risk of colorectal cancer for patients with Lynch syndrome
  • Peptest, a quick and simple test for reflux
  • Skimune, a test for adverse immune reactions to compounds including chemical cosmetics and novel pharmaceuticals
Hyperfused mitochondria and DNA

Spin-out companies

We have an excellent track record for producing spin out companies from applied research with a significant role in the development of new products and services. Spin out companies also contribute to the development and vitality of the region through new jobs and revenue creation.